Chronic myelomonocytic leukemia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:98823C93.1
Who is this for?
Show terms as
2FDA treatments25Active trials64Specialists8Treatment centers

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

CMML
Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Mar 2026Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — EARLY_PHASE1

TrialRECRUITING
Jan 2026A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

BioLite, Inc. — PHASE2

TrialNOT YET RECRUITING
Aug 2025The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes

Peking University People's Hospital

TrialNOT YET RECRUITING
Apr 2025Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center — PHASE2

TrialRECRUITING
Jan 2025A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

M.D. Anderson Cancer Center — PHASE2

TrialRECRUITING
Jan 2025Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

City of Hope Medical Center — PHASE1

TrialRECRUITING
Nov 2024IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. — PHASE3

TrialRECRUITING
Apr 2024Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Fox Chase Cancer Center — PHASE1

TrialRECRUITING
Dec 2023A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Otsuka Australia Pharmaceutical Pty Ltd — PHASE3

TrialACTIVE NOT RECRUITING
Oct 2023Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

Groupe Francophone des Myelodysplasies — PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Azacitidine

AZACITIDINE FOR· Pilnova Pharma Inc

indicated for the treatment of adult patients with chronic myelomonocytic leukemia (CMMoL)

View Details →FDA Label ↗

Azacitidine

AZACITIDINE· Dr. Reddy's Laboratories Inc.

indicated for treatment of adult patients with chronic myelomonocytic leukemia (CMMoL)

View Details →FDA Label ↗

Clinical Trials

20 recruitingView all trials with filters →
Phase 34 trials
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
Phase 3
Actively Recruiting
PI: zhijian xiao, PHD (Institute of Hematology and Blood Disease Hospital) · Sites: Hefei, Anhui; Beijing, Beijing Municipality +41 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Phase 3
Active
PI: Amit K Verma (ECOG-ACRIN Cancer Research Group) · Sites: Birmingham, Alabama; Anchorage, Alaska +506 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
Phase 3
Active
PI: Johannes Schetelig, Prof Dr med (Universitätsklinikum Dresden) · Sites: Aachen; Augsburg +21 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Phase 3
Active
PI: Anoop Enjeti (Calvary Mater Newcastle, Edith Street, Waratah, NS) · Sites: Newcastle, New South Wales; Benowa, Queensland +9 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 29 trials
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
Phase 2
Active
PI: Raphaël ITZYKSON, MD/PhD (Hôpital Saint Louis) · Sites: Amiens; Angers +22 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Phase 2
Active
PI: Rory M Shallis (Yale University Cancer Center LAO) · Sites: Phoenix, Arizona; Costa Mesa, California +32 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Phase 2
Active
PI: Mikkael A Sekeres (SWOG Cancer Research Network) · Sites: Birmingham, Alabama; Mobile, Alabama +292 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
Phase 2
Active
PI: Ami Patel, MD (Huntsman Cancer Institute) · Sites: Portland, Oregon; Salt Lake City, Utah +1 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Phase 2
Actively Recruiting
PI: Kelly Chien, MD (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Phase 2
Active
PI: Eric Padron, MD (H. Lee Moffitt Cancer Center and Research Institut) · Sites: Tampa, Florida; Baltimore, Maryland +3 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Phase 2
Actively Recruiting
PI: Guillermo Garcia-Manero (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients
Phase 2
Active
PI: Valeria Santini, MD (University of Florence- AOU Careggi) · Sites: Florence · Age: 65–100 yrs
View on ClinicalTrials.gov ↗I'm interested →
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Phase 2
Actively Recruiting
PI: Monzr M. Al Malki (City of Hope Medical Center) · Sites: Duarte, California · Age: 18–80 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 11 trial
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Phase 1
Actively Recruiting
PI: Judy Chiao, MD (Epigenetix, Inc.) · Sites: Phoenix, Arizona; Jacksonville, Florida +4 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 64View all specialists →
HM
Hagop Kantarjian, MD
HOUSTON, TX
Specialist
PI on 7 active trials
NM
Naval Daver, MD
HOUSTON, TX
Specialist
PI on 8 active trials
JM
Jorge Cortes, MD
Specialist
PI on 17 active trials
FM
Farhad Ravandi-Kashani, MD
HOUSTON, TX
Specialist
PI on 8 active trials
AM
Abhay Singh, MD, MPH
Cleveland, Ohio
Specialist

Rare Disease Specialist

PI on 1 active trial
BS
Bart Scott
SEATTLE, WA
Specialist
PI on 3 active trials
TM
Thomas G. Martin, MD
Specialist
PI on 4 active trials
JP
Jiri Pavlu
Specialist
PI on 1 active trial
GG
Guillermo Garcia-Manero
HOUSTON, TX
Specialist
PI on 9 active trials
SM
Steven Devine, MD
LA CROSSE, WI
Specialist
PI on 4 active trials
MS
Mikkael A Sekeres
MIAMI, FL
Specialist
PI on 1 active trial3 Chronic myelomonocytic leukemia publications
GM
Guillermo M Bravo, MD
CHANDLER, AZ
Specialist
PI on 1 active trial1 Chronic myelomonocytic leukemia publication
SM
Susan K. Parsons, MD, MRP
Specialist
PI on 1 active trial
FG
Francis Giles
SAN ANTONIO, TX
Specialist
PI on 4 active trials
MM
Margaret MacMillan, MD
Specialist
PI on 4 active trials
AV
Amit K Verma
Specialist
PI on 2 active trials
NS
Nicholas Short
Specialist
PI on 4 active trials
CD
Christopher Dvorak
AURORA, IL
Specialist
PI on 1 active trial
HM
Hagop M Kantarjian, MD
HOUSTON, TX
Specialist
PI on 2 active trials
EM
Eytan Stein, MD
NEW YORK, NY
Specialist
PI on 2 active trials
MR
Michele S Redell
HOUSTON, TX
Specialist
PI on 1 active trial
OO
Olatoyosi Odenike
CHICAGO, IL
Specialist
PI on 6 active trials
MM
Mignon Loh, MD
SAN FRANCISCO, CA
Specialist
PI on 2 active trials
MM
Margaret L. MacMillan, MD
Specialist
PI on 4 active trials
XM
Xiao-Hui Zhang, MD
Specialist
PI on 16 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Chronic myelomonocytic leukemia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Chronic myelomonocytic leukemiaForum →

No community posts yet. Be the first to share your experience with Chronic myelomonocytic leukemia.

Start the conversation →

Latest news about Chronic myelomonocytic leukemia

Disease timeline:

New recruiting trial: A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

A new clinical trial is recruiting patients for Chronic myelomonocytic leukemia

New recruiting trial: Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

A new clinical trial is recruiting patients for Chronic myelomonocytic leukemia

New recruiting trial: Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

A new clinical trial is recruiting patients for Chronic myelomonocytic leukemia

New recruiting trial: Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

A new clinical trial is recruiting patients for Chronic myelomonocytic leukemia

New recruiting trial: Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

A new clinical trial is recruiting patients for Chronic myelomonocytic leukemia

New recruiting trial: Austrian Myeloid Registry

A new clinical trial is recruiting patients for Chronic myelomonocytic leukemia

New recruiting trial: CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

A new clinical trial is recruiting patients for Chronic myelomonocytic leukemia

New recruiting trial: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

A new clinical trial is recruiting patients for Chronic myelomonocytic leukemia

New recruiting trial: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

A new clinical trial is recruiting patients for Chronic myelomonocytic leukemia

New recruiting trial: Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

A new clinical trial is recruiting patients for Chronic myelomonocytic leukemia

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Chronic myelomonocytic leukemia

Are there clinical trials for Chronic myelomonocytic leukemia?

Yes — 20 recruiting clinical trials are currently listed for Chronic myelomonocytic leukemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Chronic myelomonocytic leukemia?

25 specialists and care centers treating Chronic myelomonocytic leukemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.